Search

Your search keyword '"Allekotte, Silke"' showing total 42 results

Search Constraints

Start Over You searched for: Author "Allekotte, Silke" Remove constraint Author: "Allekotte, Silke"
42 results on '"Allekotte, Silke"'

Search Results

1. Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients

5. A randomized, double‐blind, placebo‐controlled trial with mannan‐conjugated birch pollen allergoids.

8. Subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids is safe and well tolerated – data from 3 sequential trials

9. Mannan-conjugated birch pollen allergoids reduce the combined symptom and medication score in birch pollen allergic patients already in the first treatment year and further decreases with prolonged treatment duration

11. Subcutaneous immunotherapy with mannan-conjugated birch pollen allergens shows long-term effects already after 2 years of treatment by inducing a significant immune response in birch pollen allergic patients

13. Correlation of the combined symptom and medication score with quality of life, symptom severity and symptom control in allergic rhinoconjunctivitis

14. COVID-19: Azelastine nasal spray Reduces Virus-load In Nasal swabs (CARVIN) Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients – results from a randomized, double-blind, placebo-controlled phase II clinical trial.

15. Correlation of the combined symptom and medication score with quality of life, symptom severity and symptom control in allergic rhinoconjunctivitis

17. Short-Course Allergen-Specific Immunotherapy with Modified Grass/Tree Allergoids Using a Microcrystalline Tyrosine (MCT®) and Monophosphoryl Lipid A (MPL) Adjuvant System Decreases Specific Immunoglobulin E Levels.

18. COVID-19: Azelastine nasal spray Reduces Virus-load In Nasal swabs (CARVIN). Early intervention with azelastine nasal sprays reduces viral load in SARS-CoV-2 infected patients. First report on a double-blind placebo-controlled phase II clinical trial.

20. A meta‐analysis on allergen‐specific immunotherapy using MCT ® (MicroCrystalline Tyrosine)‐adsorbed allergoids in pollen allergic patients suffering from allergic rhinoconjunctivitis

21. A meta-analysis on allergen-specific immunotherapy using MCT(R) (MicroCrystalline Tyrosine)-adsorbed allergoids in pollen allergic patients suffering from allergic rhinoconjunctivitis

23. MOESM2 of Subcutaneous immunotherapy with depigmented-polymerized allergen extracts: a systematic review and meta-analysis

26. A meta‐analysis on allergen‐specific immunotherapy using MCT® (MicroCrystalline Tyrosine)‐adsorbed allergoids in pollen allergic patients suffering from allergic rhinoconjunctivitis.

27. Subcutaneous immunotherapy with depigmented-polymerized allergen extracts: a systematic review and meta-analysis

28. Liposomal Eye Spray Is as Effective as Antihistamine Eye Drops in Patients with Allergic Rhinoconjunctivitis Induced by Conjunctival Provocation Testing

29. Shortened up-dosing with sublingual immunotherapy drops containing tree allergens is well tolerated and elicits dose-dependent clinical effects during the first pollen season

31. Early nonreactivity in the conjunctival provocation test predicts beneficial outcome of sublingual immunotherapy

32. Facilitated Allergen Binding (FAB) Is a Meaningful Immunological Biomarker for Monitoring Immediate Clinical Efficacy in Short-Term Peptide Allergen Immunotherapy

33. Quality management in a clinical research facility: Evaluation of changes in quality in-house figures and the appraisal of in-house quality indicators

34. Facilitated Allergen Binding (FAB) Is a Meaningful Immunological Biomarker for Monitoring Immediate Clinical Efficacy in Short-Term Peptide Allergen Immunotherapy

35. Digitally Analyzed Conjunctival Redness: Does Repeated Conjunctival Provocation Intrinsically Cause Local Desensitization of the Eye?

39. Digitally Analyzed Conjunctival Redness: Does Repeated Conjunctival Provocation Intrinsically Cause Local Desensitization of the Eye?

41. Short‐course subcutaneous treatment with birch pollen allergoids greatly improves symptom and medication scores in birch allergy.

42. XXIV World Allergy Congress 2015

Catalog

Books, media, physical & digital resources